R&D | April 29, 2026
Evonik and Higuchi launch “Open Pharma Lab” in Yokohama to accelerate oral drug Innovation
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
